Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Removal of Regulation S restrictions from shares of common stock
LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that restrictive legends have today been removed from the Company's 136,097,064 shares of common stock of US$0.001 each of the Company ("Common Stock"). The Common Stock was previously 'Regulation S' stock and restricted as defined in Rule 144 of the US Securities Act of 1933.
The Company's line of Common Stock with ISIN number USU8457V1099 is now unrestricted, save for shares held by certain controlling shareholders (principally the Directors and officers) and affiliates of the Company who will be required to maintain certain restrictions.
Spectral has no Common Stock in treasury, therefore 136,097,064 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Company's Certificate of Incorporation.
For further information please contact:
| Spectral MD Holdings, Ltd. | investors.spectralmd.com | |
| Wensheng Fan, Chief Executive Officer | via Walbrook PR | |
| Nils Windler, Chief Financial Officer |
| |
|
|
| |
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 | |
| Stuart Gledhill/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Sales & Broking)
Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown |
Tel: +44 (0) 20 7710 7600 | |
|
|
| |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | |
| Paul McManus / Sam Allen Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7407 804 654 | |
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.